EnWave Corp (ENW)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:EnWave Corp (ENW) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013379
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:33
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
EnWave Corp (EnWave) is an advanced technology company that provides industrial-scale dehydration technology for commercial applications in the pharmaceutical and food industries. It designs, constructs, markets and sells microwavevacuum biomaterial and food dehydration machines that use proprietary dehydration technologies developed by EnWave. The company introduced radiant energy vacuum (REV) as the new dehydration standard in the biological material and food sectors. EnWave has three commercial REV platforms, namely, nutraREV, which is used in the food industry; powderREV, which is used for the bulk dehydration of food cultures, probiotics and fine biochemical; and quantaREV, which is used for continuous, high-volume low-temperature drying. EnWave is headquartered in Vancouver, British Columbia, Canada.

EnWave Corp (ENW) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
EnWave Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
EnWave Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
EnWave Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
EnWave Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
EnWave Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
EnWave Corp, Pharmaceuticals & Healthcare, Deal Details 10
Licensing Agreements 10
EnWave Enters into Licensing Agreement with Major Canadian Medical Cannabis Licensed Producer 10
EnWave Enters into License Agreement with Sutro Biopharma for powderREV Technology 11
EnWave Enters into Licensing Agreement with Merck 12
EnWave Enters Into Licensing Agreement With North American Enzyme Company 13
Equity Offering 14
EnWave Raises USD7.2 Million in Public Offering of Units 14
EnWave Raises USD0.6 Million in Private Placement of Units 16
EnWave Raises USD0.14 Million in Private Placement of Shares 17
EnWave Completes Private Placement Of Units For US$7.4 Million 18
EnWave Completes Final Tranche Of Private Placement Of Shares For US$0.5 Million 19
EnWave Completes Private Placement Of Its Units For US$12.2 Million 20
EnWave Raises US$2.2 Million From Exercise Of Warrants 21
EnWave Corp – Key Competitors 22
EnWave Corp – Key Employees 23
EnWave Corp – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 25
Financial Announcements 25
Aug 25, 2017: EnWave Announces 2017 Third Quarter Consolidated Interim Financial Results 25
May 26, 2017: EnWave Announces 2017 Second Quarter Consolidated Interim Financial Results 26
Feb 24, 2017: EnWave Announces 2017 First Quarter Consolidated Interim Financial Results 27
Dec 16, 2016: EnWave Reports 2016 Annual Financial Results 28
Aug 26, 2016: EnWave Announces 2016 Third Quarter Consolidated Interim Financial Results 30
May 26, 2016: EnWave Announces First Quarterly Positive Net Income and Reports Consolidated Interim Financial Results for the Second Quarter Fiscal Year 2016 31
Feb 26, 2016: EnWave Reports Consolidated Interim Financial Results for the First Quarter Fiscal Year 2016 32
Appendix 33
Methodology 33
About GlobalData 33
Contact Us 33
Disclaimer 33

List of Tables
EnWave Corp, Pharmaceuticals & Healthcare, Key Facts, 2016 2
EnWave Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
EnWave Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
EnWave Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
EnWave Corp, Deals By Therapy Area, 2011 to YTD 2017 8
EnWave Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
EnWave Enters into Licensing Agreement with Major Canadian Medical Cannabis Licensed Producer 10
EnWave Enters into License Agreement with Sutro Biopharma for powderREV Technology 11
EnWave Enters into Licensing Agreement with Merck 12
EnWave Enters Into Licensing Agreement With North American Enzyme Company 13
EnWave Raises USD7.2 Million in Public Offering of Units 14
EnWave Raises USD0.6 Million in Private Placement of Units 16
EnWave Raises USD0.14 Million in Private Placement of Shares 17
EnWave Completes Private Placement Of Units For US$7.4 Million 18
EnWave Completes Final Tranche Of Private Placement Of Shares For US$0.5 Million 19
EnWave Completes Private Placement Of Its Units For US$12.2 Million 20
EnWave Raises US$2.2 Million From Exercise Of Warrants 21
EnWave Corp, Key Competitors 22
EnWave Corp, Key Employees 23
EnWave Corp, Subsidiaries 24

★海外企業調査レポート[EnWave Corp (ENW)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Famous Brands Limited (Foodservice):企業の戦略・SWOT・財務情報
    Famous Brands Limited (Foodservice) - Strategy, SWOT and Corporate Finance Report Summary Famous Brands Limited (Foodservice) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • National Cancer Centre Singapore:製薬・医療:M&Aディール及び事業提携情報
    Summary National Cancer Centre Singapore (NCCS) is a cancer research centre that offers research, education, clinical services, and patient care services. The centre offers services such as medical oncology, oncologic imaging, palliative medicine, pharmacy, psychosocial oncology, public education, r …
  • Mylan N.V.:企業のM&A・事業提携・投資動向
    Mylan N.V. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Mylan N.V. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …
  • Alkermes Plc (ALKS):企業の財務・戦略的SWOT分析
    Alkermes Plc (ALKS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Denny’s Corporation:戦略・SWOT・企業財務分析
    Denny's Corporation - Strategy, SWOT and Corporate Finance Report Summary Denny's Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Liebherr-International AG:企業の戦略・SWOT・財務分析
    Liebherr-International AG - Strategy, SWOT and Corporate Finance Report Summary Liebherr-International AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Brainsway Ltd (BRIN):企業の財務・戦略的SWOT分析
    Summary Brainsway Ltd (Brainsway) is a medical device company that develops and markets transcranial magnetic stimulation systems and noninvasive medical device for treatment of neurological and psychopathological disorders. The company provides deep transcranial magnetic stimulation products. It of …
  • Collegium Pharmaceutical Inc (COLL):医療機器:M&Aディール及び事業提携情報
    Summary Collegium Pharmaceutical Inc (Collegium) is a specialty pharmaceutical company that focuses on the development and commercialization of innovative products for treating patients suffering from pain. The company develops products based on its DETERx platform technology. DETERx offers extended …
  • Asian Hotels (North) Limited:企業の戦略・SWOT・財務情報
    Asian Hotels (North) Limited - Strategy, SWOT and Corporate Finance Report Summary Asian Hotels (North) Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Arab Petroleum Investments Corp:企業の戦略的SWOT分析
    Arab Petroleum Investments Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Underwriters Laboratories Inc.:企業のM&A・事業提携・投資動向
    Underwriters Laboratories Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Underwriters Laboratories Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers a …
  • Insmed Inc (INSM)-医療機器分野:企業M&A・提携分析
    Summary Insmed Inc (Insmed) is a biopharmaceutical company that focuses on rare diseases. Its lead product candidate, Arikayce (liposomal amikacin for inhalation), is indicated for the treatment of nontuberculous mycobacteria (NTM) lung disease in adult patients. Its other clinical pipeline includes …
  • VGI Global Media Public Co Ltd:企業の戦略・SWOT・財務情報
    VGI Global Media Public Co Ltd - Strategy, SWOT and Corporate Finance Report Summary VGI Global Media Public Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Kartonsan Karton Sanayi ve Ticaret A.S.:企業の戦略・SWOT・財務情報
    Kartonsan Karton Sanayi ve Ticaret A.S. - Strategy, SWOT and Corporate Finance Report Summary Kartonsan Karton Sanayi ve Ticaret A.S. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • CARBO Ceramics Inc (CRR):企業の財務・戦略的SWOT分析
    CARBO Ceramics Inc (CRR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Oxiteno SA Industria E Comercio:企業の戦略的SWOT分析
    Oxiteno SA Industria E Comercio - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Syndax Pharmaceuticals Inc (SNDX)-医療機器分野:企業M&A・提携分析
    Summary Syndax Pharmaceuticals Inc (Syndax) is aclinical stage biopharmaceutical company that develops and commercializes therapies for multiple cancer indications. The company’s lead product candidate, entinostat, an oral, small molecule drug candidate, which is in phase 3 clinical trial used for t …
  • GEE Group Inc (JOB):企業の財務・戦略的SWOT分析
    Summary GEE Group Inc (GEE) is a provider of professional staffing and recruiting services. The company’s staffing services comprise temporary staffing services, professional placement services, and management services. It provides direct hire, contract, and contract-to-hire services in accounting, …
  • Etihad Aviation Group PJSC:企業の戦略・SWOT・財務情報
    Etihad Aviation Group PJSC - Strategy, SWOT and Corporate Finance Report Summary Etihad Aviation Group PJSC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Biosceptre International Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Biosceptre International Ltd (Biosceptre) is a biotechnology company that develops antibody technologies for applications in the diagnosis and treatment of cancer. The company develops imaging technologies to detect and monitor cancer. Its diagnostic products are used for the detection of va …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆